Dec 15, 2022 Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Nov 08, 2022 Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Aug 12, 2022 Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Jun 16, 2022 Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
Jun 06, 2022 Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2022 Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 13, 2022 Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency